nodes	percent_of_prediction	percent_of_DWPC	metapath
Agomelatine—CYP2C9—Nilutamide—prostate cancer	0.0857	0.165	CbGbCtD
Agomelatine—CYP2C9—Bicalutamide—prostate cancer	0.0857	0.165	CbGbCtD
Agomelatine—CYP1A2—Flutamide—prostate cancer	0.0788	0.152	CbGbCtD
Agomelatine—CYP1A2—Estrone—prostate cancer	0.057	0.11	CbGbCtD
Agomelatine—CYP2C9—Estrone—prostate cancer	0.0513	0.0991	CbGbCtD
Agomelatine—CYP2C9—Capecitabine—prostate cancer	0.0389	0.0751	CbGbCtD
Agomelatine—CYP1A2—Conjugated Estrogens—prostate cancer	0.0373	0.0719	CbGbCtD
Agomelatine—CYP1A2—Estradiol—prostate cancer	0.0327	0.0631	CbGbCtD
Agomelatine—CYP2C9—Estradiol—prostate cancer	0.0295	0.0569	CbGbCtD
Agomelatine—CYP1A2—Etoposide—prostate cancer	0.0214	0.0412	CbGbCtD
Agomelatine—Melatonin—CALR—prostate cancer	0.00227	0.229	CrCbGaD
Agomelatine—Nabumetone—MPO—prostate cancer	0.00112	0.113	CrCbGaD
Agomelatine—Naproxen—AKR1C3—prostate cancer	0.00111	0.112	CrCbGaD
Agomelatine—Indomethacin—AKR1C3—prostate cancer	0.000898	0.0906	CrCbGaD
Agomelatine—Indomethacin—PPARA—prostate cancer	0.000778	0.0785	CrCbGaD
Agomelatine—Indomethacin—CXCL8—prostate cancer	0.000539	0.0544	CrCbGaD
Agomelatine—Melatonin—CYP1B1—prostate cancer	0.000495	0.05	CrCbGaD
Agomelatine—Melatonin—MPO—prostate cancer	0.000446	0.045	CrCbGaD
Agomelatine—Nabumetone—PTGS2—prostate cancer	0.00042	0.0424	CrCbGaD
Agomelatine—Melatonin—CYP19A1—prostate cancer	0.000363	0.0367	CrCbGaD
Agomelatine—Melatonin—ESR1—prostate cancer	0.000334	0.0338	CrCbGaD
Agomelatine—Jaundice—Capecitabine—prostate cancer	0.000301	0.00108	CcSEcCtD
Agomelatine—Blood alkaline phosphatase increased—Doxorubicin—prostate cancer	0.000297	0.00107	CcSEcCtD
Agomelatine—Infection—Mitoxantrone—prostate cancer	0.000292	0.00105	CcSEcCtD
Agomelatine—Hepatobiliary disease—Capecitabine—prostate cancer	0.000292	0.00105	CcSEcCtD
Agomelatine—Back pain—Etoposide—prostate cancer	0.00029	0.00104	CcSEcCtD
Agomelatine—Nausea—Ethinyl Estradiol—prostate cancer	0.000287	0.00103	CcSEcCtD
Agomelatine—Eczema—Doxorubicin—prostate cancer	0.000287	0.00103	CcSEcCtD
Agomelatine—Hepatic failure—Doxorubicin—prostate cancer	0.000287	0.00103	CcSEcCtD
Agomelatine—Hepatitis—Docetaxel—prostate cancer	0.000286	0.00103	CcSEcCtD
Agomelatine—Asthenia—Goserelin—prostate cancer	0.000286	0.00103	CcSEcCtD
Agomelatine—Skin disorder—Mitoxantrone—prostate cancer	0.000286	0.00103	CcSEcCtD
Agomelatine—Insomnia—Estradiol—prostate cancer	0.000286	0.00102	CcSEcCtD
Agomelatine—Hyperhidrosis—Mitoxantrone—prostate cancer	0.000284	0.00102	CcSEcCtD
Agomelatine—Paraesthesia—Estradiol—prostate cancer	0.000283	0.00102	CcSEcCtD
Agomelatine—Asthenia—Conjugated Estrogens—prostate cancer	0.000283	0.00102	CcSEcCtD
Agomelatine—Pruritus—Goserelin—prostate cancer	0.000282	0.00101	CcSEcCtD
Agomelatine—Connective tissue disorder—Docetaxel—prostate cancer	0.000281	0.00101	CcSEcCtD
Agomelatine—Somnolence—Estradiol—prostate cancer	0.000281	0.00101	CcSEcCtD
Agomelatine—Weight increased—Prednisone—prostate cancer	0.000281	0.00101	CcSEcCtD
Agomelatine—Pruritus—Conjugated Estrogens—prostate cancer	0.000279	0.001	CcSEcCtD
Agomelatine—Weight decreased—Prednisone—prostate cancer	0.000279	0.001	CcSEcCtD
Agomelatine—Dyspepsia—Estradiol—prostate cancer	0.000278	0.000997	CcSEcCtD
Agomelatine—Hepatitis—Capecitabine—prostate cancer	0.000277	0.000994	CcSEcCtD
Agomelatine—Migraine—Epirubicin—prostate cancer	0.000275	0.000986	CcSEcCtD
Agomelatine—Depression—Prednisone—prostate cancer	0.000274	0.000984	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Estradiol—prostate cancer	0.000273	0.000978	CcSEcCtD
Agomelatine—Diarrhoea—Goserelin—prostate cancer	0.000272	0.000978	CcSEcCtD
Agomelatine—Connective tissue disorder—Capecitabine—prostate cancer	0.000272	0.000977	CcSEcCtD
Agomelatine—Fatigue—Estradiol—prostate cancer	0.000272	0.000977	CcSEcCtD
Agomelatine—Constipation—Estradiol—prostate cancer	0.00027	0.000969	CcSEcCtD
Agomelatine—Diarrhoea—Conjugated Estrogens—prostate cancer	0.00027	0.000969	CcSEcCtD
Agomelatine—Face oedema—Epirubicin—prostate cancer	0.000269	0.000967	CcSEcCtD
Agomelatine—Vertigo—Etoposide—prostate cancer	0.000269	0.000967	CcSEcCtD
Agomelatine—Melatonin—CYP2C19—prostate cancer	0.000268	0.0271	CrCbGaD
Agomelatine—Eye disorder—Docetaxel—prostate cancer	0.000267	0.00096	CcSEcCtD
Agomelatine—Melatonin—CYP1A1—prostate cancer	0.000267	0.027	CrCbGaD
Agomelatine—Paraesthesia—Mitoxantrone—prostate cancer	0.000264	0.000948	CcSEcCtD
Agomelatine—Dizziness—Goserelin—prostate cancer	0.000263	0.000945	CcSEcCtD
Agomelatine—Somnolence—Mitoxantrone—prostate cancer	0.000261	0.000938	CcSEcCtD
Agomelatine—Dizziness—Conjugated Estrogens—prostate cancer	0.000261	0.000936	CcSEcCtD
Agomelatine—Eye disorder—Capecitabine—prostate cancer	0.000259	0.000929	CcSEcCtD
Agomelatine—Dyspepsia—Mitoxantrone—prostate cancer	0.000259	0.000929	CcSEcCtD
Agomelatine—Tinnitus—Capecitabine—prostate cancer	0.000258	0.000927	CcSEcCtD
Agomelatine—Gastrointestinal pain—Estradiol—prostate cancer	0.000258	0.000926	CcSEcCtD
Agomelatine—Migraine—Doxorubicin—prostate cancer	0.000254	0.000912	CcSEcCtD
Agomelatine—Fatigue—Mitoxantrone—prostate cancer	0.000254	0.00091	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.000253	0.00091	CcSEcCtD
Agomelatine—Vomiting—Goserelin—prostate cancer	0.000253	0.000909	CcSEcCtD
Agomelatine—Indomethacin—CYP2C19—prostate cancer	0.000253	0.0255	CrCbGaD
Agomelatine—Constipation—Mitoxantrone—prostate cancer	0.000252	0.000903	CcSEcCtD
Agomelatine—Vomiting—Conjugated Estrogens—prostate cancer	0.000251	0.0009	CcSEcCtD
Agomelatine—Urticaria—Estradiol—prostate cancer	0.000251	0.0009	CcSEcCtD
Agomelatine—Mental disorder—Docetaxel—prostate cancer	0.000251	0.0009	CcSEcCtD
Agomelatine—Abdominal pain—Estradiol—prostate cancer	0.00025	0.000896	CcSEcCtD
Agomelatine—Nasopharyngitis—Epirubicin—prostate cancer	0.00025	0.000896	CcSEcCtD
Agomelatine—Headache—Goserelin—prostate cancer	0.000249	0.000895	CcSEcCtD
Agomelatine—Face oedema—Doxorubicin—prostate cancer	0.000249	0.000895	CcSEcCtD
Agomelatine—Headache—Conjugated Estrogens—prostate cancer	0.000247	0.000887	CcSEcCtD
Agomelatine—Hallucination—Prednisone—prostate cancer	0.000246	0.000881	CcSEcCtD
Agomelatine—Infection—Etoposide—prostate cancer	0.000243	0.000872	CcSEcCtD
Agomelatine—Mental disorder—Capecitabine—prostate cancer	0.000243	0.000871	CcSEcCtD
Agomelatine—Connective tissue disorder—Prednisone—prostate cancer	0.000243	0.00087	CcSEcCtD
Agomelatine—Influenza—Epirubicin—prostate cancer	0.000241	0.000866	CcSEcCtD
Agomelatine—Back pain—Docetaxel—prostate cancer	0.000241	0.000865	CcSEcCtD
Agomelatine—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000241	0.000863	CcSEcCtD
Agomelatine—Skin disorder—Etoposide—prostate cancer	0.000238	0.000853	CcSEcCtD
Agomelatine—Nausea—Goserelin—prostate cancer	0.000237	0.000849	CcSEcCtD
Agomelatine—Hyperhidrosis—Etoposide—prostate cancer	0.000237	0.000849	CcSEcCtD
Agomelatine—Nausea—Conjugated Estrogens—prostate cancer	0.000234	0.000841	CcSEcCtD
Agomelatine—Urticaria—Mitoxantrone—prostate cancer	0.000234	0.000839	CcSEcCtD
Agomelatine—Back pain—Capecitabine—prostate cancer	0.000233	0.000837	CcSEcCtD
Agomelatine—Abdominal pain—Mitoxantrone—prostate cancer	0.000233	0.000835	CcSEcCtD
Agomelatine—Nasopharyngitis—Doxorubicin—prostate cancer	0.000231	0.000829	CcSEcCtD
Agomelatine—Eye disorder—Prednisone—prostate cancer	0.000231	0.000828	CcSEcCtD
Agomelatine—Vision blurred—Capecitabine—prostate cancer	0.000227	0.000816	CcSEcCtD
Agomelatine—Asthenia—Estradiol—prostate cancer	0.000226	0.000813	CcSEcCtD
Agomelatine—Tremor—Capecitabine—prostate cancer	0.000226	0.000811	CcSEcCtD
Agomelatine—Pruritus—Estradiol—prostate cancer	0.000223	0.000802	CcSEcCtD
Agomelatine—Influenza—Doxorubicin—prostate cancer	0.000223	0.000801	CcSEcCtD
Agomelatine—Paraesthesia—Etoposide—prostate cancer	0.00022	0.000788	CcSEcCtD
Agomelatine—Weight increased—Epirubicin—prostate cancer	0.000219	0.000788	CcSEcCtD
Agomelatine—Weight decreased—Epirubicin—prostate cancer	0.000218	0.000783	CcSEcCtD
Agomelatine—Somnolence—Etoposide—prostate cancer	0.000218	0.000781	CcSEcCtD
Agomelatine—Vertigo—Capecitabine—prostate cancer	0.000217	0.000778	CcSEcCtD
Agomelatine—Mental disorder—Prednisone—prostate cancer	0.000216	0.000776	CcSEcCtD
Agomelatine—Diarrhoea—Estradiol—prostate cancer	0.000216	0.000775	CcSEcCtD
Agomelatine—Infestation NOS—Epirubicin—prostate cancer	0.000215	0.000772	CcSEcCtD
Agomelatine—Infestation—Epirubicin—prostate cancer	0.000215	0.000772	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Etoposide—prostate cancer	0.000211	0.000758	CcSEcCtD
Agomelatine—Asthenia—Mitoxantrone—prostate cancer	0.000211	0.000757	CcSEcCtD
Agomelatine—Fatigue—Etoposide—prostate cancer	0.000211	0.000757	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	0.000211	0.000756	CcSEcCtD
Agomelatine—Jaundice—Epirubicin—prostate cancer	0.00021	0.000752	CcSEcCtD
Agomelatine—Constipation—Etoposide—prostate cancer	0.000209	0.000751	CcSEcCtD
Agomelatine—Dizziness—Estradiol—prostate cancer	0.000209	0.000749	CcSEcCtD
Agomelatine—Dry mouth—Docetaxel—prostate cancer	0.000207	0.000744	CcSEcCtD
Agomelatine—Anxiety—Capecitabine—prostate cancer	0.000205	0.000734	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	0.000204	0.000732	CcSEcCtD
Agomelatine—Hepatobiliary disease—Epirubicin—prostate cancer	0.000203	0.00073	CcSEcCtD
Agomelatine—Weight increased—Doxorubicin—prostate cancer	0.000203	0.000729	CcSEcCtD
Agomelatine—Vision blurred—Prednisone—prostate cancer	0.000202	0.000727	CcSEcCtD
Agomelatine—Infection—Docetaxel—prostate cancer	0.000202	0.000725	CcSEcCtD
Agomelatine—Weight decreased—Doxorubicin—prostate cancer	0.000202	0.000725	CcSEcCtD
Agomelatine—Diarrhoea—Mitoxantrone—prostate cancer	0.000201	0.000722	CcSEcCtD
Agomelatine—Dry mouth—Capecitabine—prostate cancer	0.000201	0.000721	CcSEcCtD
Agomelatine—Vomiting—Estradiol—prostate cancer	0.000201	0.00072	CcSEcCtD
Agomelatine—Gastrointestinal pain—Etoposide—prostate cancer	0.0002	0.000718	CcSEcCtD
Agomelatine—Nervous system disorder—Docetaxel—prostate cancer	0.000199	0.000716	CcSEcCtD
Agomelatine—Infestation NOS—Doxorubicin—prostate cancer	0.000199	0.000714	CcSEcCtD
Agomelatine—Infestation—Doxorubicin—prostate cancer	0.000199	0.000714	CcSEcCtD
Agomelatine—Headache—Estradiol—prostate cancer	0.000198	0.00071	CcSEcCtD
Agomelatine—Skin disorder—Docetaxel—prostate cancer	0.000198	0.000709	CcSEcCtD
Agomelatine—Agitation—Prednisone—prostate cancer	0.000197	0.000709	CcSEcCtD
Agomelatine—Angioedema—Prednisone—prostate cancer	0.000196	0.000705	CcSEcCtD
Agomelatine—Infection—Capecitabine—prostate cancer	0.000196	0.000702	CcSEcCtD
Agomelatine—Urticaria—Etoposide—prostate cancer	0.000194	0.000698	CcSEcCtD
Agomelatine—Naproxen—PTGS2—prostate cancer	0.000194	0.0196	CrCbGaD
Agomelatine—Jaundice—Doxorubicin—prostate cancer	0.000194	0.000696	CcSEcCtD
Agomelatine—Abdominal pain—Etoposide—prostate cancer	0.000193	0.000694	CcSEcCtD
Agomelatine—Nervous system disorder—Capecitabine—prostate cancer	0.000193	0.000693	CcSEcCtD
Agomelatine—Vertigo—Prednisone—prostate cancer	0.000193	0.000693	CcSEcCtD
Agomelatine—Hepatitis—Epirubicin—prostate cancer	0.000193	0.000693	CcSEcCtD
Agomelatine—Skin disorder—Capecitabine—prostate cancer	0.000191	0.000686	CcSEcCtD
Agomelatine—Hyperhidrosis—Capecitabine—prostate cancer	0.00019	0.000683	CcSEcCtD
Agomelatine—Connective tissue disorder—Epirubicin—prostate cancer	0.00019	0.000681	CcSEcCtD
Agomelatine—Hepatobiliary disease—Doxorubicin—prostate cancer	0.000188	0.000675	CcSEcCtD
Agomelatine—Nausea—Estradiol—prostate cancer	0.000188	0.000673	CcSEcCtD
Agomelatine—Vomiting—Mitoxantrone—prostate cancer	0.000187	0.000671	CcSEcCtD
Agomelatine—Headache—Mitoxantrone—prostate cancer	0.000184	0.000661	CcSEcCtD
Agomelatine—Insomnia—Docetaxel—prostate cancer	0.000184	0.00066	CcSEcCtD
Agomelatine—Paraesthesia—Docetaxel—prostate cancer	0.000183	0.000655	CcSEcCtD
Agomelatine—Anxiety—Prednisone—prostate cancer	0.000182	0.000654	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	0.000182	0.000652	CcSEcCtD
Agomelatine—Somnolence—Docetaxel—prostate cancer	0.000181	0.000649	CcSEcCtD
Agomelatine—Eye disorder—Epirubicin—prostate cancer	0.00018	0.000647	CcSEcCtD
Agomelatine—Tinnitus—Epirubicin—prostate cancer	0.00018	0.000646	CcSEcCtD
Agomelatine—Dyspepsia—Docetaxel—prostate cancer	0.000179	0.000642	CcSEcCtD
Agomelatine—Hepatitis—Doxorubicin—prostate cancer	0.000179	0.000641	CcSEcCtD
Agomelatine—Insomnia—Capecitabine—prostate cancer	0.000178	0.000639	CcSEcCtD
Agomelatine—Paraesthesia—Capecitabine—prostate cancer	0.000177	0.000634	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000176	0.00063	CcSEcCtD
Agomelatine—Asthenia—Etoposide—prostate cancer	0.000176	0.00063	CcSEcCtD
Agomelatine—Connective tissue disorder—Doxorubicin—prostate cancer	0.000176	0.00063	CcSEcCtD
Agomelatine—Fatigue—Docetaxel—prostate cancer	0.000175	0.000629	CcSEcCtD
Agomelatine—Nausea—Mitoxantrone—prostate cancer	0.000175	0.000627	CcSEcCtD
Agomelatine—Infection—Prednisone—prostate cancer	0.000174	0.000625	CcSEcCtD
Agomelatine—Constipation—Docetaxel—prostate cancer	0.000174	0.000624	CcSEcCtD
Agomelatine—Dyspepsia—Capecitabine—prostate cancer	0.000173	0.000622	CcSEcCtD
Agomelatine—Pruritus—Etoposide—prostate cancer	0.000173	0.000621	CcSEcCtD
Agomelatine—Nervous system disorder—Prednisone—prostate cancer	0.000172	0.000617	CcSEcCtD
Agomelatine—Skin disorder—Prednisone—prostate cancer	0.00017	0.000611	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Capecitabine—prostate cancer	0.00017	0.00061	CcSEcCtD
Agomelatine—Fatigue—Capecitabine—prostate cancer	0.00017	0.000609	CcSEcCtD
Agomelatine—Hyperhidrosis—Prednisone—prostate cancer	0.00017	0.000608	CcSEcCtD
Agomelatine—Mental disorder—Epirubicin—prostate cancer	0.000169	0.000607	CcSEcCtD
Agomelatine—Constipation—Capecitabine—prostate cancer	0.000168	0.000604	CcSEcCtD
Agomelatine—Diarrhoea—Etoposide—prostate cancer	0.000167	0.000601	CcSEcCtD
Agomelatine—Eye disorder—Doxorubicin—prostate cancer	0.000167	0.000599	CcSEcCtD
Agomelatine—Tinnitus—Doxorubicin—prostate cancer	0.000167	0.000598	CcSEcCtD
Agomelatine—Gastrointestinal pain—Docetaxel—prostate cancer	0.000166	0.000597	CcSEcCtD
Agomelatine—Back pain—Epirubicin—prostate cancer	0.000163	0.000583	CcSEcCtD
Agomelatine—Dizziness—Etoposide—prostate cancer	0.000162	0.000581	CcSEcCtD
Agomelatine—Gastrointestinal pain—Capecitabine—prostate cancer	0.000161	0.000578	CcSEcCtD
Agomelatine—Abdominal pain—Docetaxel—prostate cancer	0.000161	0.000577	CcSEcCtD
Agomelatine—Insomnia—Prednisone—prostate cancer	0.000159	0.000569	CcSEcCtD
Agomelatine—Vision blurred—Epirubicin—prostate cancer	0.000158	0.000568	CcSEcCtD
Agomelatine—Paraesthesia—Prednisone—prostate cancer	0.000157	0.000565	CcSEcCtD
Agomelatine—Indomethacin—PTGS2—prostate cancer	0.000157	0.0159	CrCbGaD
Agomelatine—Mental disorder—Doxorubicin—prostate cancer	0.000156	0.000562	CcSEcCtD
Agomelatine—Urticaria—Capecitabine—prostate cancer	0.000156	0.000561	CcSEcCtD
Agomelatine—Abdominal pain—Capecitabine—prostate cancer	0.000156	0.000559	CcSEcCtD
Agomelatine—Vomiting—Etoposide—prostate cancer	0.000156	0.000558	CcSEcCtD
Agomelatine—Agitation—Epirubicin—prostate cancer	0.000154	0.000554	CcSEcCtD
Agomelatine—Dyspepsia—Prednisone—prostate cancer	0.000154	0.000554	CcSEcCtD
Agomelatine—Headache—Etoposide—prostate cancer	0.000153	0.00055	CcSEcCtD
Agomelatine—Fatigue—Prednisone—prostate cancer	0.000151	0.000543	CcSEcCtD
Agomelatine—Vertigo—Epirubicin—prostate cancer	0.000151	0.000542	CcSEcCtD
Agomelatine—Back pain—Doxorubicin—prostate cancer	0.00015	0.00054	CcSEcCtD
Agomelatine—Constipation—Prednisone—prostate cancer	0.00015	0.000538	CcSEcCtD
Agomelatine—Vision blurred—Doxorubicin—prostate cancer	0.000147	0.000526	CcSEcCtD
Agomelatine—Asthenia—Docetaxel—prostate cancer	0.000146	0.000524	CcSEcCtD
Agomelatine—Nausea—Etoposide—prostate cancer	0.000145	0.000522	CcSEcCtD
Agomelatine—Pruritus—Docetaxel—prostate cancer	0.000144	0.000516	CcSEcCtD
Agomelatine—Gastrointestinal pain—Prednisone—prostate cancer	0.000143	0.000515	CcSEcCtD
Agomelatine—Agitation—Doxorubicin—prostate cancer	0.000143	0.000513	CcSEcCtD
Agomelatine—Anxiety—Epirubicin—prostate cancer	0.000143	0.000512	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	0.000142	0.00051	CcSEcCtD
Agomelatine—Asthenia—Capecitabine—prostate cancer	0.000141	0.000507	CcSEcCtD
Agomelatine—Dry mouth—Epirubicin—prostate cancer	0.00014	0.000502	CcSEcCtD
Agomelatine—Vertigo—Doxorubicin—prostate cancer	0.00014	0.000501	CcSEcCtD
Agomelatine—Urticaria—Prednisone—prostate cancer	0.000139	0.0005	CcSEcCtD
Agomelatine—Pruritus—Capecitabine—prostate cancer	0.000139	0.0005	CcSEcCtD
Agomelatine—Diarrhoea—Docetaxel—prostate cancer	0.000139	0.000499	CcSEcCtD
Agomelatine—Abdominal pain—Prednisone—prostate cancer	0.000139	0.000497	CcSEcCtD
Agomelatine—Infection—Epirubicin—prostate cancer	0.000136	0.000489	CcSEcCtD
Agomelatine—Diarrhoea—Capecitabine—prostate cancer	0.000135	0.000483	CcSEcCtD
Agomelatine—Nervous system disorder—Epirubicin—prostate cancer	0.000134	0.000483	CcSEcCtD
Agomelatine—Dizziness—Docetaxel—prostate cancer	0.000134	0.000483	CcSEcCtD
Agomelatine—Skin disorder—Epirubicin—prostate cancer	0.000133	0.000478	CcSEcCtD
Agomelatine—Hyperhidrosis—Epirubicin—prostate cancer	0.000133	0.000476	CcSEcCtD
Agomelatine—Anxiety—Doxorubicin—prostate cancer	0.000132	0.000473	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	0.000131	0.000472	CcSEcCtD
Agomelatine—Dizziness—Capecitabine—prostate cancer	0.00013	0.000467	CcSEcCtD
Agomelatine—Dry mouth—Doxorubicin—prostate cancer	0.000129	0.000465	CcSEcCtD
Agomelatine—Vomiting—Docetaxel—prostate cancer	0.000129	0.000464	CcSEcCtD
Agomelatine—Headache—Docetaxel—prostate cancer	0.000127	0.000457	CcSEcCtD
Agomelatine—Infection—Doxorubicin—prostate cancer	0.000126	0.000452	CcSEcCtD
Agomelatine—Asthenia—Prednisone—prostate cancer	0.000126	0.000452	CcSEcCtD
Agomelatine—Vomiting—Capecitabine—prostate cancer	0.000125	0.000449	CcSEcCtD
Agomelatine—Nervous system disorder—Doxorubicin—prostate cancer	0.000124	0.000447	CcSEcCtD
Agomelatine—Pruritus—Prednisone—prostate cancer	0.000124	0.000445	CcSEcCtD
Agomelatine—Insomnia—Epirubicin—prostate cancer	0.000124	0.000445	CcSEcCtD
Agomelatine—Headache—Capecitabine—prostate cancer	0.000123	0.000443	CcSEcCtD
Agomelatine—Skin disorder—Doxorubicin—prostate cancer	0.000123	0.000442	CcSEcCtD
Agomelatine—Paraesthesia—Epirubicin—prostate cancer	0.000123	0.000442	CcSEcCtD
Agomelatine—Hyperhidrosis—Doxorubicin—prostate cancer	0.000123	0.00044	CcSEcCtD
Agomelatine—Somnolence—Epirubicin—prostate cancer	0.000122	0.000438	CcSEcCtD
Agomelatine—Nausea—Docetaxel—prostate cancer	0.000121	0.000433	CcSEcCtD
Agomelatine—Dyspepsia—Epirubicin—prostate cancer	0.000121	0.000433	CcSEcCtD
Agomelatine—Diarrhoea—Prednisone—prostate cancer	0.00012	0.000431	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000118	0.000425	CcSEcCtD
Agomelatine—Fatigue—Epirubicin—prostate cancer	0.000118	0.000424	CcSEcCtD
Agomelatine—Constipation—Epirubicin—prostate cancer	0.000117	0.000421	CcSEcCtD
Agomelatine—Nausea—Capecitabine—prostate cancer	0.000117	0.00042	CcSEcCtD
Agomelatine—Dizziness—Prednisone—prostate cancer	0.000116	0.000416	CcSEcCtD
Agomelatine—Insomnia—Doxorubicin—prostate cancer	0.000115	0.000412	CcSEcCtD
Agomelatine—Paraesthesia—Doxorubicin—prostate cancer	0.000114	0.000409	CcSEcCtD
Agomelatine—Somnolence—Doxorubicin—prostate cancer	0.000113	0.000405	CcSEcCtD
Agomelatine—Gastrointestinal pain—Epirubicin—prostate cancer	0.000112	0.000402	CcSEcCtD
Agomelatine—Dyspepsia—Doxorubicin—prostate cancer	0.000112	0.000401	CcSEcCtD
Agomelatine—Vomiting—Prednisone—prostate cancer	0.000111	0.0004	CcSEcCtD
Agomelatine—Headache—Prednisone—prostate cancer	0.00011	0.000394	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.00011	0.000393	CcSEcCtD
Agomelatine—Fatigue—Doxorubicin—prostate cancer	0.000109	0.000393	CcSEcCtD
Agomelatine—Urticaria—Epirubicin—prostate cancer	0.000109	0.000391	CcSEcCtD
Agomelatine—Constipation—Doxorubicin—prostate cancer	0.000109	0.000389	CcSEcCtD
Agomelatine—Abdominal pain—Epirubicin—prostate cancer	0.000108	0.000389	CcSEcCtD
Agomelatine—Nausea—Prednisone—prostate cancer	0.000104	0.000374	CcSEcCtD
Agomelatine—Gastrointestinal pain—Doxorubicin—prostate cancer	0.000104	0.000372	CcSEcCtD
Agomelatine—Urticaria—Doxorubicin—prostate cancer	0.000101	0.000362	CcSEcCtD
Agomelatine—Abdominal pain—Doxorubicin—prostate cancer	0.0001	0.00036	CcSEcCtD
Agomelatine—Asthenia—Epirubicin—prostate cancer	9.84e-05	0.000353	CcSEcCtD
Agomelatine—Pruritus—Epirubicin—prostate cancer	9.7e-05	0.000348	CcSEcCtD
Agomelatine—Diarrhoea—Epirubicin—prostate cancer	9.38e-05	0.000337	CcSEcCtD
Agomelatine—Asthenia—Doxorubicin—prostate cancer	9.1e-05	0.000327	CcSEcCtD
Agomelatine—Dizziness—Epirubicin—prostate cancer	9.07e-05	0.000325	CcSEcCtD
Agomelatine—Pruritus—Doxorubicin—prostate cancer	8.98e-05	0.000322	CcSEcCtD
Agomelatine—Vomiting—Epirubicin—prostate cancer	8.72e-05	0.000313	CcSEcCtD
Agomelatine—Diarrhoea—Doxorubicin—prostate cancer	8.68e-05	0.000312	CcSEcCtD
Agomelatine—Headache—Epirubicin—prostate cancer	8.59e-05	0.000308	CcSEcCtD
Agomelatine—Dizziness—Doxorubicin—prostate cancer	8.39e-05	0.000301	CcSEcCtD
Agomelatine—Nausea—Epirubicin—prostate cancer	8.15e-05	0.000292	CcSEcCtD
Agomelatine—Vomiting—Doxorubicin—prostate cancer	8.07e-05	0.00029	CcSEcCtD
Agomelatine—Headache—Doxorubicin—prostate cancer	7.95e-05	0.000285	CcSEcCtD
Agomelatine—Nausea—Doxorubicin—prostate cancer	7.54e-05	0.000271	CcSEcCtD
Agomelatine—HTR2C—Signaling Pathways—ADRB2—prostate cancer	1.32e-05	6.84e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SLC22A1—prostate cancer	1.32e-05	6.83e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	1.31e-05	6.75e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—JAK2—prostate cancer	1.3e-05	6.75e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—MAP2K1—prostate cancer	1.3e-05	6.72e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—prostate cancer	1.3e-05	6.71e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTA2—prostate cancer	1.29e-05	6.69e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CD—prostate cancer	1.29e-05	6.68e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—VAV3—prostate cancer	1.29e-05	6.67e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SULT2A1—prostate cancer	1.29e-05	6.66e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—IL2—prostate cancer	1.28e-05	6.63e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ABCG5—prostate cancer	1.28e-05	6.61e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SULT1A1—prostate cancer	1.28e-05	6.61e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TERT—prostate cancer	1.28e-05	6.6e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TGFBR2—prostate cancer	1.27e-05	6.58e-05	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—AKT1—prostate cancer	1.27e-05	6.58e-05	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—AKT1—prostate cancer	1.27e-05	6.58e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—MED12—prostate cancer	1.27e-05	6.55e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GNG5—prostate cancer	1.26e-05	6.5e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ITPR1—prostate cancer	1.25e-05	6.47e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTA1—prostate cancer	1.25e-05	6.45e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CB—prostate cancer	1.24e-05	6.41e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NAT2—prostate cancer	1.23e-05	6.38e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTO1—prostate cancer	1.23e-05	6.38e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—HSD3B2—prostate cancer	1.23e-05	6.38e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HIF1A—prostate cancer	1.22e-05	6.31e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NCOA3—prostate cancer	1.21e-05	6.26e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IGF1R—prostate cancer	1.2e-05	6.19e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—LEP—prostate cancer	1.19e-05	6.16e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—CXCL8—prostate cancer	1.19e-05	6.16e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.19e-05	6.15e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PPARA—prostate cancer	1.19e-05	6.14e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—JAK2—prostate cancer	1.18e-05	6.13e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—LRP2—prostate cancer	1.18e-05	6.12e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PLCB2—prostate cancer	1.18e-05	6.12e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP2C18—prostate cancer	1.18e-05	6.12e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CAV1—prostate cancer	1.18e-05	6.11e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KDR—prostate cancer	1.17e-05	6.04e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—P4HB—prostate cancer	1.16e-05	6e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—HPGDS—prostate cancer	1.15e-05	5.97e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP2C19—prostate cancer	1.15e-05	5.93e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—LPL—prostate cancer	1.15e-05	5.93e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—IL2—prostate cancer	1.14e-05	5.89e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ESR1—prostate cancer	1.14e-05	5.88e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PDGFRB—prostate cancer	1.14e-05	5.88e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SLC22A1—prostate cancer	1.13e-05	5.84e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CB—prostate cancer	1.13e-05	5.82e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ACHE—prostate cancer	1.12e-05	5.79e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTT1—prostate cancer	1.12e-05	5.79e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—prostate cancer	1.12e-05	5.77e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—BAD—prostate cancer	1.11e-05	5.74e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ITGB3—prostate cancer	1.11e-05	5.73e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP2A6—prostate cancer	1.11e-05	5.72e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.1e-05	5.7e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SULT2A1—prostate cancer	1.1e-05	5.69e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—MED12—prostate cancer	1.08e-05	5.6e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—CXCL8—prostate cancer	1.08e-05	5.59e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—AKR1C3—prostate cancer	1.08e-05	5.57e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CG—prostate cancer	1.08e-05	5.56e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—APC—prostate cancer	1.08e-05	5.56e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ERBB3—prostate cancer	1.07e-05	5.56e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GNG5—prostate cancer	1.07e-05	5.55e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—FGFR2—prostate cancer	1.07e-05	5.55e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PRKACB—prostate cancer	1.07e-05	5.54e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—EGF—prostate cancer	1.06e-05	5.5e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IRS1—prostate cancer	1.06e-05	5.5e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP17A1—prostate cancer	1.06e-05	5.48e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.05e-05	5.41e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NCOA3—prostate cancer	1.03e-05	5.35e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—IL2—prostate cancer	1.03e-05	5.35e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—GSK3B—prostate cancer	1.03e-05	5.34e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TERT—prostate cancer	1.03e-05	5.33e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—INS—prostate cancer	1.02e-05	5.27e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.02e-05	5.26e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NCOA2—prostate cancer	1.01e-05	5.22e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CREBBP—prostate cancer	9.97e-06	5.16e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—HPGDS—prostate cancer	9.86e-06	5.1e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HIF1A—prostate cancer	9.85e-06	5.09e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IGF1—prostate cancer	9.84e-06	5.09e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP2C19—prostate cancer	9.8e-06	5.07e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—EGFR—prostate cancer	9.8e-06	5.07e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SLC5A5—prostate cancer	9.63e-06	4.98e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—LEP—prostate cancer	9.61e-06	4.97e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ACHE—prostate cancer	9.57e-06	4.95e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTT1—prostate cancer	9.57e-06	4.95e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CAV1—prostate cancer	9.52e-06	4.93e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MAP2K1—prostate cancer	9.51e-06	4.92e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP2A6—prostate cancer	9.46e-06	4.89e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CD—prostate cancer	9.45e-06	4.89e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	9.42e-06	4.87e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KDR—prostate cancer	9.42e-06	4.87e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP2E1—prostate cancer	9.41e-06	4.87e-05	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—PIK3CA—prostate cancer	9.36e-06	4.84e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SERPINE1—prostate cancer	9.35e-06	4.84e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NQO1—prostate cancer	9.3e-06	4.81e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—KRAS—prostate cancer	9.25e-06	4.79e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—AKR1C3—prostate cancer	9.2e-06	4.76e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ESR1—prostate cancer	9.18e-06	4.75e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—TH—prostate cancer	9.17e-06	4.74e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PRKACB—prostate cancer	9.15e-06	4.73e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	9.11e-06	4.71e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP3A4—prostate cancer	9.07e-06	4.69e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP17A1—prostate cancer	9.05e-06	4.68e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—FGF2—prostate cancer	9.05e-06	4.68e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	9.03e-06	4.67e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—BAD—prostate cancer	8.96e-06	4.63e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	8.93e-06	4.62e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NOS3—prostate cancer	8.93e-06	4.62e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP1B1—prostate cancer	8.92e-06	4.61e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—JAK2—prostate cancer	8.67e-06	4.49e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—APC—prostate cancer	8.67e-06	4.49e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CG—prostate cancer	8.67e-06	4.49e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GGT1—prostate cancer	8.64e-06	4.47e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NCOA2—prostate cancer	8.63e-06	4.46e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—EGF—prostate cancer	8.57e-06	4.44e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IRS1—prostate cancer	8.57e-06	4.44e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NCOA1—prostate cancer	8.51e-06	4.4e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PIK3CA—prostate cancer	8.5e-06	4.4e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MDM2—prostate cancer	8.47e-06	4.38e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP19A1—prostate cancer	8.39e-06	4.34e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ERBB2—prostate cancer	8.35e-06	4.32e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—GSK3B—prostate cancer	8.32e-06	4.31e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CB—prostate cancer	8.24e-06	4.26e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SLC5A5—prostate cancer	8.23e-06	4.26e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—INS—prostate cancer	8.21e-06	4.25e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—RXRA—prostate cancer	8.09e-06	4.19e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CREBBP—prostate cancer	8.04e-06	4.16e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP2E1—prostate cancer	8.04e-06	4.16e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NQO1—prostate cancer	7.95e-06	4.11e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IGF1—prostate cancer	7.94e-06	4.11e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CXCL8—prostate cancer	7.92e-06	4.1e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—EGFR—prostate cancer	7.9e-06	4.09e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	7.87e-06	4.07e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—TH—prostate cancer	7.83e-06	4.05e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—COMT—prostate cancer	7.8e-06	4.03e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	7.78e-06	4.03e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTP1—prostate cancer	7.76e-06	4.01e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP3A4—prostate cancer	7.75e-06	4.01e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CDKN1B—prostate cancer	7.73e-06	4e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	7.71e-06	3.99e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MAP2K1—prostate cancer	7.68e-06	3.97e-05	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—AKT1—prostate cancer	7.65e-06	3.96e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ITPR1—prostate cancer	7.63e-06	3.95e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CD—prostate cancer	7.63e-06	3.95e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP1B1—prostate cancer	7.62e-06	3.94e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CASP3—prostate cancer	7.58e-06	3.92e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL2—prostate cancer	7.57e-06	3.91e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PIK3CA—prostate cancer	7.55e-06	3.91e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SERPINE1—prostate cancer	7.54e-06	3.9e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—IL6—prostate cancer	7.53e-06	3.89e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	7.51e-06	3.88e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—KRAS—prostate cancer	7.47e-06	3.86e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GGT1—prostate cancer	7.38e-06	3.82e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CCND1—prostate cancer	7.38e-06	3.82e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CTNNB1—prostate cancer	7.3e-06	3.78e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—FGF2—prostate cancer	7.3e-06	3.78e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NCOA1—prostate cancer	7.27e-06	3.76e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—TYMS—prostate cancer	7.21e-06	3.73e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NOS3—prostate cancer	7.2e-06	3.73e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP19A1—prostate cancer	7.17e-06	3.71e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MMP9—prostate cancer	7.16e-06	3.7e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CDKN1A—prostate cancer	7.14e-06	3.69e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTM1—prostate cancer	7.13e-06	3.69e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PTEN—prostate cancer	7.12e-06	3.68e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—LPL—prostate cancer	7e-06	3.62e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—JAK2—prostate cancer	7e-06	3.62e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—AKT1—prostate cancer	6.95e-06	3.59e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—RXRA—prostate cancer	6.92e-06	3.58e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PIK3CA—prostate cancer	6.86e-06	3.55e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MDM2—prostate cancer	6.83e-06	3.53e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—EP300—prostate cancer	6.79e-06	3.51e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP1A1—prostate cancer	6.76e-06	3.5e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ERBB2—prostate cancer	6.74e-06	3.48e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	6.73e-06	3.48e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ERCC2—prostate cancer	6.7e-06	3.47e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—COMT—prostate cancer	6.66e-06	3.45e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CB—prostate cancer	6.65e-06	3.44e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTP1—prostate cancer	6.63e-06	3.43e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SRC—prostate cancer	6.6e-06	3.42e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ITPR1—prostate cancer	6.52e-06	3.38e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—VEGFA—prostate cancer	6.43e-06	3.33e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	6.41e-06	3.32e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CXCL8—prostate cancer	6.39e-06	3.3e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—STAT3—prostate cancer	6.37e-06	3.29e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—MTHFR—prostate cancer	6.3e-06	3.26e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CDKN1B—prostate cancer	6.24e-06	3.23e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PPARA—prostate cancer	6.18e-06	3.2e-05	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—AKT1—prostate cancer	6.17e-06	3.19e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—TYMS—prostate cancer	6.16e-06	3.19e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CASP3—prostate cancer	6.11e-06	3.16e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL2—prostate cancer	6.1e-06	3.16e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTM1—prostate cancer	6.09e-06	3.15e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—IL6—prostate cancer	6.07e-06	3.14e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—LPL—prostate cancer	5.98e-06	3.09e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CCND1—prostate cancer	5.95e-06	3.08e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MYC—prostate cancer	5.92e-06	3.06e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TGFB1—prostate cancer	5.9e-06	3.05e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CTNNB1—prostate cancer	5.89e-06	3.05e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CAV1—prostate cancer	5.81e-06	3.01e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—EGFR—prostate cancer	5.79e-06	2.99e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MMP9—prostate cancer	5.78e-06	2.99e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP1A1—prostate cancer	5.78e-06	2.99e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CDKN1A—prostate cancer	5.76e-06	2.98e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTEN—prostate cancer	5.74e-06	2.97e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ERCC2—prostate cancer	5.73e-06	2.96e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—AKT1—prostate cancer	5.6e-06	2.9e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	5.55e-06	2.87e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—EP300—prostate cancer	5.48e-06	2.83e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KRAS—prostate cancer	5.47e-06	2.83e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—MTHFR—prostate cancer	5.38e-06	2.79e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SRC—prostate cancer	5.33e-06	2.76e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CG—prostate cancer	5.29e-06	2.74e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PPARA—prostate cancer	5.28e-06	2.73e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—VEGFA—prostate cancer	5.19e-06	2.68e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—STAT3—prostate cancer	5.14e-06	2.66e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PIK3CA—prostate cancer	5.02e-06	2.6e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—INS—prostate cancer	5.01e-06	2.59e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CAV1—prostate cancer	4.97e-06	2.57e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CREBBP—prostate cancer	4.91e-06	2.54e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TP53—prostate cancer	4.86e-06	2.51e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MYC—prostate cancer	4.77e-06	2.47e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TGFB1—prostate cancer	4.76e-06	2.46e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	4.75e-06	2.46e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—EGFR—prostate cancer	4.67e-06	2.42e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CD—prostate cancer	4.65e-06	2.41e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CG—prostate cancer	4.52e-06	2.34e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL6—prostate cancer	4.45e-06	2.3e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KRAS—prostate cancer	4.41e-06	2.28e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NOS3—prostate cancer	4.39e-06	2.27e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—INS—prostate cancer	4.28e-06	2.22e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CREBBP—prostate cancer	4.19e-06	2.17e-05	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—AKT1—prostate cancer	4.1e-06	2.12e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CB—prostate cancer	4.06e-06	2.1e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	4.05e-06	2.1e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTGS2—prostate cancer	4.02e-06	2.08e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CD—prostate cancer	3.98e-06	2.06e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TP53—prostate cancer	3.92e-06	2.03e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NOS3—prostate cancer	3.76e-06	1.94e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL6—prostate cancer	3.59e-06	1.86e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTEN—prostate cancer	3.51e-06	1.81e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CB—prostate cancer	3.47e-06	1.79e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTGS2—prostate cancer	3.43e-06	1.78e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—EP300—prostate cancer	3.34e-06	1.73e-05	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—AKT1—prostate cancer	3.31e-06	1.71e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTEN—prostate cancer	3e-06	1.55e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—EP300—prostate cancer	2.86e-06	1.48e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PIK3CA—prostate cancer	2.47e-06	1.28e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PIK3CA—prostate cancer	2.11e-06	1.09e-05	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—AKT1—prostate cancer	2.02e-06	1.05e-05	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—AKT1—prostate cancer	1.73e-06	8.93e-06	CbGpPWpGaD
